RE: Data mining11 Mar 2022 10:05
Here’s what JC said on the San Diego RNS………
"The Board believes that these changes align management with the strategic direction outlined at the time of our recent £6m fundraising and optimally leverage expertise with the needs of the Company. Scancell's next generation cancer vaccine platforms, ImmunoBody® and Moditope®, are delivering outstanding results and I am convinced that Scancell will secure wider recognition for its innovative technologies and products in both the United States and Europe over the coming months."
That was back in May 2016 but in all fairness, we are still in the “coming months” :-)